Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin AVitamin A (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Vitamin A for COVID-19: real-time meta analysis of 19 studies (13 treatment studies and 6 sufficiency studies)

@CovidAnalysis, May 2024, Version 28V28
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Rohani (DB RCT) 26% 0.74 [0.31-1.76] hosp. 8/89 11/91 Rohani (DB RCT) 32% 0.68 [0.20-2.33] no recov. 4/89 6/91 Rohani (DB RCT) 80% 0.20 [0.05-0.91] no recov. 2/89 10/91 Rohani (DB RCT) 87% 0.13 [0.03-0.61] no recov. 1/89 8/91 Rohani (DB RCT) 49% 0.51 [0.13-1.98] no recov. 3/89 6/91 Rohani (DB RCT) 63% 0.37 [0.12-1.12] no recov. 4/89 11/91 Rohani (DB RCT) 20% 0.80 [0.31-2.04] no recov. 7/89 9/91 Rohani (DB RCT) 40% 0.60 [0.25-1.45] no recov. 7/89 12/91 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] death 0/30 4/30 ICU patients CT​1 Beigm.. (SB RCT) 41% 0.59 [0.17-1.28] hosp. 4/30 16/30 ICU patients CT​1 Beigm.. (SB RCT) 45% 0.55 [0.38-0.78] SOFA 30 (n) 30 (n) ICU patients CT​1 Somi (RCT) -50% 1.50 [0.29-7.73] death 3/15 2/15 Somi (RCT) 0% 1.00 [0.24-4.18] ventilation 3/15 3/15 Somi (RCT) 25% 0.75 [0.20-2.79] ICU 3/15 4/15 Somi (RCT) -76% 1.76 [0.73-4.26] no improv. 15 (n) 15 (n) Somi (RCT) -8% 1.08 [0.87-1.34] hosp. time 15 (n) 15 (n) Doocy 26% 0.74 [0.11-4.80] death 1/8 23/136 Chung (RCT) 75% 0.25 [0.06-0.99] PASC 9 (n) 8 (n) LONG COVID Chung (RCT) 68% 0.32 [0.01-6.90] PASC 0/9 1/8 LONG COVID Chung (RCT) 70% 0.30 [0.04-2.31] PASC 1/9 3/8 LONG COVID Chung (RCT) 75% 0.25 [0.07-0.89] PASC 2/9 7/8 LONG COVID Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 COVIDENCE UK Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Nimer 21% 0.79 [0.45-1.35] hosp. 15/144 204/2,004 Nimer 21% 0.79 [0.46-1.30] severe case 17/144 243/2,004 Vaisi 17% 0.83 [0.48-1.00] hosp. 1,140 (n) 2,815 (n) Vaisi 11% 0.89 [0.69-0.98] symp. case 1,140 (n) 2,815 (n) Wang 35% 0.65 [0.30-1.40] severe case n/a n/a Mendelian - per SD Wang 24% 0.76 [0.46-1.25] hosp. n/a n/a Mendelian - per SD Wang 31% 0.69 [0.53-0.90] cases n/a n/a Mendelian - per SD Vitamin A COVID-19 outcomes c19early.org May 2024 1 CT: study uses combined treatment Favors vitamin A Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit